Author + information
- Received April 21, 2017
- Revision received July 17, 2017
- Accepted July 26, 2017
- Published online October 2, 2017.
- Clemens Metzea,
- Anna-Sophie Matzika,
- Maximilian Scherner, MDb,
- Maria Isabel Körber, MDa,
- Guido Michels, MDa,
- Stephan Baldus, MDa,
- Volker Rudolph, MDa and
- Roman Pfister, MDa,∗ ()
- aDepartment III of Internal Medicine, Heart Center, University of Cologne, Cologne, Germany
- bDepartment of Cardiothoracic Surgery, Heart Center, University of Cologne, Cologne, Germany
- ↵∗Address for correspondence:
Prof. Dr. Roman Pfister, University of Cologne, Heart Center, Department III of Internal Medicine, Kerpener Strasse 62, 50937 Cologne, Germany.
Objectives The aim of this study was to describe the impact of frailty in patients undergoing percutaneous mitral valve repair (PMVR).
Background Frailty is common in elderly patients and those with comorbidities and is associated with adverse prognosis.
Methods Frailty according to the Fried criteria was assessed in consecutive patients admitted for PMVR. Associations of frailty with 6-week (device success, changes in 6-min walking distance and Minnesota Living With Heart Failure Questionnaire and Short Form 36 physical and mental component scores, and improvement ≥1 New York Heart Association functional class) and long-term outcomes during a median follow-up period of 429 days were examined.
Results Of 213 patients admitted for PMVR (median age 78 years; age range 50 to 95 years; 57.3% men), 45.5% were classified as frail. Compared with nonfrail patients, frail patients had a similar device success rate (81.4% vs. 84.5%; p = 0.56) and improvement in 6-min walking distance, New York Heart Association functional class, and Short Form-36 scores but a more pronounced improvement in Minnesota Living With Heart Failure Questionnaire score (mean change −15.9 vs. −11.2 points; p = 0.002). Mortality at 6 weeks was significantly higher in frail (8.3%) compared with nonfrail (1.7%) patients (p = 0.03). Hazards of death (hazard ratio: 3.06; 95% confidence interval: 1.54 to 6.07; p = 0.001) and death or heart failure decompensation (hazard ratio: 2.03; 95% confidence interval: 1.22 to 3.39; p = 0.007) were significantly increased in frail patients during long-term follow-up, which did not change relevantly after adjustment for European System for Cardiac Operative Risk Evaluation score and N-terminal pro–brain natriuretic peptide level.
Conclusions PMVR can be performed with equal efficacy and is associated with at least similar short-term functional improvement in frail patients. These results support the continued use of PMVR in frail elderly patients with the goal of palliation of heart failure symptoms and improvement in quality of life.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Metze, Rudolph, and Pfister contributed equally to this work.
- Received April 21, 2017.
- Revision received July 17, 2017.
- Accepted July 26, 2017.
- 2017 American College of Cardiology Foundation